Phase II Trial of Gemcitabine and Docetaxel with Bevacizumab in Soft Tissue Sarcoma

Figure 1

CONSORT diagram. Patients who received gemcitabine + docetaxel (GD) and placebo were excluded from the toxicity and efficacy analysis of GD + bevacizumab.